You are here

  • Home
  • Archive
  • Volume 10, Issue 12
  • Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial

Article metrics

Article menu

This article has a correction. Please see:

Immunotherapy biomarkers
Original research
Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial

 

Online download statistics by month:

Online download statistics by month: December 2022 to July 2025

AbstractFullPdf
Dec 202234835277
Jan 2023326327138
Feb 202324824969
Mar 202322622658
Apr 202322422565
May 202323723841
Jun 202321821831
Jul 202319019038
Aug 202313513530
Sep 2023929322
Oct 2023666628
Nov 202314814830
Dec 202315915938
Jan 202412712865
Feb 202414014032
Mar 202414314369
Apr 202416516545
May 202414714934
Jun 202414915236
Jul 202413013038
Aug 202411111329
Sep 202411211234
Oct 202415215243
Nov 202412412526
Dec 202415816129
Jan 2025959528
Feb 202515015021
Mar 202515815748
Apr 202512712855
May 202513113238
Jun 2025747522
Jul 2025110
Total501150341357